Search research articles
Contact Us
Filters
Showing results (91-100 of 108) with videos related to
Page
of 11
Sort By:
ACS Medicinal Chemistry Letters
|
June 6, 2014
Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example
Markus Boehm, David Hepworth, Paula M Loria, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 13, 2005
Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands
Richard Chesworth, Matthew D Wessel, Lisa Heyden, et al.
ACS Medicinal Chemistry Letters
|
February 21, 2015
Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists
Suvi T M Orr, Ramsay Beveridge, Samit K Bhattacharya, et al.
Mabs
|
August 13, 2025
Building a potent TREM2 agonistic, biparatopic, common light chain antibody
Ana da Silva Almeida, Melissa L Geddie, Anil Bhate, et al.
Brain : a Journal of Neurology
|
June 19, 2021
MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response
Kathryn Pellerin, Stephen J Rubino, Jeremy C Burns, et al.
Mabs
|
November 25, 2025
Balancing brain exposure, pharmacokinetics and safety of transferrin receptor antibodies for delivery of neuro-therapeutics
Benjamin A Smith, Caitlin B Meeks, Isabel Murray-Brown, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 20, 2012
Discovery of new piperidine amide triazolobenzodiazepinones as intestinal-selective CCK1 receptor agonists
Kimberly O Cameron, Elena E Beretta, Yue Chen, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 21, 2010
Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity
Richard L Elliott, Kimberly O Cameron, Janice E Chin, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate
Samit K Bhattacharya, Kim Andrews, Ramsay Beveridge, et al.
Ebiomedicine
|
April 21, 2018
Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models
Ryan M Esquejo, Christopher T Salatto, Jake Delmore, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 108) with videos related to
Sort By:
Page
of 11
ACS Medicinal Chemistry Letters
|
June 6, 2014
Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example
Markus Boehm, David Hepworth, Paula M Loria, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 13, 2005
Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands
Richard Chesworth, Matthew D Wessel, Lisa Heyden, et al.
ACS Medicinal Chemistry Letters
|
February 21, 2015
Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists
Suvi T M Orr, Ramsay Beveridge, Samit K Bhattacharya, et al.
Mabs
|
August 13, 2025
Building a potent TREM2 agonistic, biparatopic, common light chain antibody
Ana da Silva Almeida, Melissa L Geddie, Anil Bhate, et al.
Brain : a Journal of Neurology
|
June 19, 2021
MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response
Kathryn Pellerin, Stephen J Rubino, Jeremy C Burns, et al.
Mabs
|
November 25, 2025
Balancing brain exposure, pharmacokinetics and safety of transferrin receptor antibodies for delivery of neuro-therapeutics
Benjamin A Smith, Caitlin B Meeks, Isabel Murray-Brown, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 20, 2012
Discovery of new piperidine amide triazolobenzodiazepinones as intestinal-selective CCK1 receptor agonists
Kimberly O Cameron, Elena E Beretta, Yue Chen, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 21, 2010
Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity
Richard L Elliott, Kimberly O Cameron, Janice E Chin, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate
Samit K Bhattacharya, Kim Andrews, Ramsay Beveridge, et al.
Ebiomedicine
|
April 21, 2018
Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models
Ryan M Esquejo, Christopher T Salatto, Jake Delmore, et al.
Page
of 11